Tuesday, June 6, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharmaceutical Antitrust

A federal judge in Connecticut granted class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

BRIDGEPORT, Conn. – A federal judge in Connecticut granted class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

Categories: Business Health

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading...